Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test
April 10, 2024 12:19 ET
|
Precede Biosciences, Inc.
Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancersTargets revealed from a...
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
March 05, 2024 16:35 ET
|
Precede Biosciences, Inc.
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced three...
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast Cancer
December 06, 2023 08:00 ET
|
Precede Biosciences, Inc.
BOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced that...
Data Demonstrating Precede Biosciences' Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023 17:02 ET
|
Precede Biosciences, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data...
Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine
October 21, 2023 04:25 ET
|
Precede Biosciences, Inc.
Pivotal findings stem from Precede’s first-in-class platform in collaboration with Dana-Farber Cancer Institute Results underscore the immense potential of the blood-based platform to impact...
Precede Biosciences Announces First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023
October 15, 2023 18:05 ET
|
Precede Biosciences, Inc.
BOSTON, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission...
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform
October 05, 2023 07:00 ET
|
Precede Biosciences, Inc.
Unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and pathways in diseased tissues from just 1mL of...